Clinical trials: Tace
Hepatocellular Carcinoma
TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study
The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with pd-1 antibody immunotherapy (Sintilimab) and anti-VEGF (Bevacizumab Biosimilar) in patients with…
- Trial name
- T-Double (NCT04796025)
- Testing
- Sintilimab; Bevacizumab Biosimilar
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation.
- Trial name
- NCT01918683
- Testing
- TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma, HCC
Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
This study will compare stereotactic body radiation therapy (SBRT) to trans-arterial chemoembolization (TACE) as a bridging strategy for patients with HCC undergoing liver transplantation.
- Trial name
- SBRTvsTACE (NCT03960008)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
- Where
- 5 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Lahey Clinic
HCC
DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial
This is a randomized controlled trial to determine the efficacy and safety of DEB-TACE versus DEB-TACE sequential HAIC for unresectable BCLC stage C HCC
- Trial name
- NCT05788835
- Testing
- DEB-TACE and HAIC, DEB-TACE
- Where
- 16 sites in China
- Volunteers
- 220 people
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment.
- Trial name
- NCT07235410
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma
PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- PLATIC (NCT04814043)
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma
This study is open to patients with primary HCC who cannot be treated by potentially curative treatment modalities, such as surgical resection, liver transplantation or percutaneous ablation.
- Trial name
- SIRTACE (NCT00867750)
- Testing
- Radioembolisation (SIR-Spheres® microspheres), Transarterial Chemoembolisation
- Where
- 2 sites in Germany, Spain
- Volunteers
- 28 people
- Sponsor
- Sirtex Medical
Hepatocellular Carcinoma, Donafenib
A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
This study is a prospective, single-center, observational real-world study. It is planned to enroll 150 patients with unresectable hepatocellular carcinoma treated with Donafenib combined with TACE-based treatment, so as to…
- Trial name
- NCT05205629
- Testing
- Donafenib combined with TACE
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
SBRT + TACE for Primary Hepatocellular Carcinoma
The purpose of this study is to determine the feasibility and toxicity of combining SBRT and TACE for unresectable HCC and to evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.
- Trial name
- NCT00746655
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Transcatheter Arterial Chemoembolization (TACE)
- Where
- 4 sites in United States
- Sponsor
- University of Pittsburgh
Carcinoma, Hepatocellular, Cirrhosis
Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging
This clinical trial is aimed at extending the chance of liver transplantation, through downstaging procedures, to patients with hepatocellular carcinoma (HCC) exceeding conventional Milan Criteria.
- Trial name
- NCT01387503
- Testing
- Liver transplantation
- Where
- 10 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Adebrelimab (SHR-1316), Bevacizumab
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic…
- Conditions
- Adebrelimab (SHR-1316), Bevacizumab, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07543783
- Testing
- Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepato Cellular Carcinoma (HCC)
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
This Phase I/II trial aims to evaluate the pharmacokinetics, efficacy, and safety of tirapazamine administered via hepatic artery injection followed by TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06848556
- Testing
- tirapazamine, Transarterial Embolization, TACE
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Hepatecellular Carcinoma, Liver Injury
HAIC vs. TACE Combined With ICIs and TKIs in Intermediate-to-Advanced HCC: A Multicenter Study on Liver Injury and Survival
The purpose of this study is to compare the liver injury induced by HAIC combined with PD-1/PD-L1 inhibitors and TKIs versus triple therapy with TACE in the treatment of patients with advanced HCC; to compare the efficacy of the…
- Conditions
- Hepatecellular Carcinoma, Liver Injury, HAIC(Hepatic Artery Infusion Chemotherapy), TACE(Transcatheter Arterial Chemoembolization)
- Trial name
- NCT07277192
- Where
- China
- Volunteers
- 562 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Neuroendocrine Cancer
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
This study is a single prospective, parallel, double-cohort, multicenter phase II clinical trial, aiming to evaluate the efficacy and safety of ivonescimab (AK112) combined with IP chemotherapy ± TACE in the first-line treatment…
- Trial name
- NCT07712094
- Testing
- AK112, Irinotecan, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Adjuvant Therapies for Patients With HCC and MVI
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades.
- Trial name
- A-TACE/S-HCC (NCT02436902)
- Testing
- TACE, Sorafenib, TACE plus sorafenib
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma (HCC)
TACE for HCC by TANDEM and Idarubicin
DcBeads and lipiodol-transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using doxorubicin result in about 50% objective response rate at 6 months (Precision V study, Lammer et al.
- Trial name
- TANDEM-IDA (NCT03349957)
- Testing
- Transarterial chemoembolization using TANDEM and idarubicin
- Where
- France
- Volunteers
- 98 people
- Sponsor
- University Hospital, Montpellier
Hepatocellular Carcinoma (HCC)
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Tumor-draining lymph nodes play an important role in anti-tumor immune responses. In patients with hepatocellular carcinoma (HCC), however, the relationship between regional lymph node metastasis (LNM) and immunotherapy-based…
- Trial name
- CHANCE2421 (NCT06876753)
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhongda Hospital
Liver Metastasis, Colorectal Cancer
Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer
The purpose of this study is to investigate whether TAC plus FOLFOX4 or TACE plus folfox4 are able to improve resection rate and overall survival in patients receiving primary colorectal tumor resection than given FOLFOX4 only.
- Trial name
- NCT00868569
- Testing
- TACE + folfox 4, TAC + folfox4
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic…
- Trial name
- NCT04246177
- Testing
- Lenvatinib, Pembrolizumab, TACE
- Where
- 205 sites in United States, Australia and 25 more
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma
The purpose of this study is to evaluate efficacy, safety, and patient reported outcomes (PRO) of different regimens of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
- Trial name
- TACEforHCC (NCT00493402)
- Testing
- Transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 365 people
- Sponsor
- Sun Yat-sen University